002294: Shenzhen Salubris Pharmaceuticals Co., Ltd. - Summary | Jitta

Shenzhen Salubris Pharmaceuticals Co., Ltd.

CHN:002294

Price
CN¥51.29
Loss Chance
47.5%
5.31JITTA SCORE
602.89%Over Jitta Line
Jitta Ranking
122 / 487
1,174 / 5,259
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (54)
Recent Business Performance (51)
Financial Strength (91)
Return to Shareholders (22)
Competitive Advantage (36)
Jitta Signs
Revenue and EarningConsistent
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
Operating MarginDeclined
Recent Business PerformanceEarning decline 0.46% in the last year
CapExVery High
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.31
602.89%
4.42
> 1,000%
4.24
> 1,000%
Pharmaceuticals
6.36
2.64%
5.47
25.22%
7.76
43.10%
COMPANY DESCRIPTION
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.